论文部分内容阅读
随着基因组学、生物化学、分子生物学及多肽合成等科学技术的发展,蛋白质及多肽药物已成为跨国医药企业竞相争夺未来生物医药领域的一个制高点。但是蛋白质类药物的临床应用受到了其理化及生物特性的种种限制,为了改善治疗效果,近年来聚合物修饰的蛋白质类药物有了长足的发展。本文着重回顾了蛋白质类药物聚乙二醇修饰的发展和现状,以及由此获得的优点和局限性;同时介绍了其它新型生物相容性聚合物蛋白质类药物修饰的最新研究进展,探讨了蛋白质类药物的“后聚乙二醇修饰”时代的可能方向和应用前景。
With the development of science and technology such as genomics, biochemistry, molecular biology and peptide synthesis, protein and peptide drugs have become a commanding height for multinational pharmaceutical companies to compete for the future biomedicine field. However, the clinical application of protein drugs has been its physical and chemical and biological characteristics of the various limitations, in order to improve the therapeutic effect, in recent years polymer modified protein drugs have made considerable progress. This review focuses on the development and current status of the PEGylation of proteinaceous drugs, and the advantages and limitations of the resulting modification. At the same time, the latest research progress on the modification of other novel biocompatible polymer proteins is introduced. The Possible Directions and Application Prospects of Drug-like “Post-Polyethylene Glycol Modification” Era.